友邦香港與四跨國藥廠合作提供額外癌症藥物保障額
友邦香港宣布,與阿斯利康香港、禮來(LLY.US)、諾華(NVS.US)及輝瑞(PFE.US)四大跨國藥廠合作,推出「攜手增益癌症藥物計劃」,為指定團體醫療保險度身訂造計劃的新客戶提供額外癌症藥物保障額。
倘受保成員罹患癌症,除可按其團體醫療保險條款獲得保障,若獲處方的抗癌藥物已列載於相關計劃的藥物名單內,便可獲得額外保障額。目前相關藥物名單中已有6款主要治療乳癌的藥物在內。
友邦香港及四間藥廠擬將計劃陸續擴展至不同層面客戶。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.